{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:13:07Z","timestamp":1790485987098,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We used a novel penile simian-human immunodeficiency virus (SHIV) transmission model to investigate whether long-acting cabotegravir (CAB LA) prevents penile SHIV acquisition in macaques. Twenty-two macaques were exposed to SHIV via the foreskin and urethra once weekly for 12 weeks. Of these, 6 received human-equivalent doses of CAB LA, 6 received oral emtricitabine\/tenofovir disoproxil fumarate, and 10 were untreated. The efficacy of CAB LA was high (94.4%; 95% confidence interval, 58.2%\u201399.3%) and similar to that seen with oral emtricitabine\/tenofovir disoproxil fumarate (94.0%; 55.1%\u201399.2%). The high efficacy of CAB LA in the penile transmission model supports extending the clinical advancement of CAB LA preexposure prophylaxis to heterosexual men.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa095","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T20:13:55Z","timestamp":1582834435000},"page":"391-395","source":"Crossref","is-referenced-by-count":19,"title":["Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures"],"prefix":"10.1093","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-1775","authenticated-orcid":false,"given":"Charles","family":"Dobard","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Makarova","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nishiura","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong","family":"Dinh","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Holder","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Sterling","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lipscomb","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mitchell","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Deyounks","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garber","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Khalil","sequence":"first","affiliation":[{"name":"Quantitative Sciences and Data Management Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spreen","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Heneine","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Gerardo","family":"Garc\u00eda-Lerma","sequence":"first","affiliation":[{"name":"Laboratory Branch, Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"2020070607241561000_CIT0001","volume-title":"HIV Surveillance Report, 2018 (Preliminary)","author":"Centers for Disease Control and Prevention"},{"key":"2020070607241561000_CIT0002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)60313-4","article-title":"Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial","volume":"369","author":"Gray","year":"2007","journal-title":"Lancet"},{"key":"2020070607241561000_CIT0003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"2020070607241561000_CIT0004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"2020070607241561000_CIT0005","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"2020070607241561000_CIT0006","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews","year":"2014","journal-title":"Science"},{"key":"2020070607241561000_CIT0007","doi-asserted-by":"crossref","first-page":"270ra5","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio","year":"2015","journal-title":"Sci Transl Med"},{"key":"2020070607241561000_CIT0008","doi-asserted-by":"crossref","first-page":"e0194837","DOI":"10.1371\/journal.pone.0194837","article-title":"Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV","volume":"13","author":"Garber","year":"2018","journal-title":"PLoS One"},{"key":"2020070607241561000_CIT0009","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JVI.05842-11","article-title":"Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue","volume":"86","author":"Dobard","year":"2012","journal-title":"J Virol"},{"key":"2020070607241561000_CIT0010","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garc\u00eda-Lerma","year":"2008","journal-title":"PLoS Med"},{"key":"2020070607241561000_CIT0011","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1086\/507306","article-title":"Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges","volume":"194","author":"Subbarao","year":"2006","journal-title":"J Infect Dis"},{"key":"2020070607241561000_CIT0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med"},{"key":"2020070607241561000_CIT0013","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QAD.0b013e328321b778","article-title":"HIV-1 infection of human penile explant tissue and protection by candidate microbicides","volume":"23","author":"Fischetti","year":"2009","journal-title":"AIDS"},{"key":"2020070607241561000_CIT0014","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/01.aids.0000237364.11123.98","article-title":"Potential HIV-1 target cells in the human penis","volume":"20","author":"McCoombe","year":"2006","journal-title":"AIDS"},{"key":"2020070607241561000_CIT0015","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41467-019-10047-w","article-title":"Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection","volume":"10","author":"Radzio-Basu","year":"2019","journal-title":"Nat Commun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa095\/32963138\/jiaa095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/3\/391\/33466244\/jiaa095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/3\/391\/33466244\/jiaa095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:24:38Z","timestamp":1594034678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/3\/391\/5780064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,4]]},"published-print":{"date-parts":[[2020,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa095","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,1]]},"published":{"date-parts":[[2020,3,4]]}}}